Alnylam Pharmaceuticals: Its Advancement of ALN-6400 Hemostatic Program

Alnylam Pharmaceuticals’ third quarter of 2025 highlighted a significant period of growth and strategic execution for the company. This growth is seen across various aspects of their business model, including commercial performance, pipeline advancements, and financial outcomes. However, it is also a period marked by substantial commitments to future success, which carry their own set of risks and uncertainties. On the positive side, Alnylam reported robust financial metrics with total net product revenues reaching $851 million, marking a 103% increase year-over-year. This impressive growth is largely driven by their transthyretin (TTR) franchise. The U.S. launch of AMVUTTRA for ATTR cardiomyopathy appears particularly successful, with TTR revenues amounting to $724 million, a 135% increase from the previous year. This success underlines strategic execution and the effectiveness of the company’s approach in establishing a foothold in the cardiomyopathy treatment sector.